NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE MULTIPLE SCLEROSIS MEDICINE TERIFLUNOMIDE IN CANADA

We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Teriflunomide for a market entry on day one after patent expiration in Canada.

Teriflunomide is used to improve the life of patients suffering from Multiple Sclerosis – a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in TIEFENBACHER GROUPs own site in India and will be marketed in Canada by our partners, two well-known generic pharmaceutical companies. Our product has already been launched in time in Australia before – a launch in further international markets will follow as soon as the patents of the originator product expire. With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com

 


TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)

We at TIEFENBACHER GROUP are committed to promote sustainable and responsible business along the whole pharmaceutical supply chain. That’s why we are excited to become a member of PSCI – a non-profit business membership organization striving for better social, health, safety, and environmental outcomes in pharmaceutical supply chains. It follows our company´s strategy to make medicines better affordable, better available, and better than before in a sustainable way – better for people and the planet!

PSCI is a group of international pharmaceutical and healthcare companies who share together the vision of responsible supply chains. The organization was founded in 2006 and is legally established in the United States. Today PSCI already counts 63 members. For more information about the organization have a look at: PSCI (pscinitiative.org) .

For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA

TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for TIEFENBACHER GROUP to become a leading global developer and manufacturer of highly potent drugs for the treatment of cancer and other diseases. It follows our company´s strategy to make medicines more affordable, more available, and better than before.

The lab is equipped with the latest techniques with full safety protection measurements and will be extended by an additional manufacturing block with special technologies in 2023. The new complex will cover a total of about 4.000 square meters.

TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in the new facilities in Hyderabad. While the operational start of the lab (including small-scale production) is planned for this year, the commercial production for larger quantities in the new manufacturing block is expected for 2024.

For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


WORLD HEALTH DAY @ TIEFENBACHER GROUP

Today we celebrate World Health Day. In times of a global pandemic and a cruel war in Europe, it is more important than ever that we all work together to create a healthier tomorrow. Since 1963 we at TIEFENBACHER GROUP are pioneering healthcare to improve patients´ lives around the world. Today we serve over 500 million patients every year with our pharmaceutical products and innovative healthcare solutions. In everything we do we are led by three questions: are we making high-quality pharmaceuticals better affordable, better globally available, or better than before?

For information about our product portfolio and innovative healthcare solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve
patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!

One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP presenting our latest product portfolio and innovations to our existing and potential new partners. Check out our short video to get some impressions!

For further information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE EPILEPSY MEDICINE LACOSAMIDE IN AUSTRALIA

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their income level or nationality. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Lacosamide for a market entry on day one after patent expiration in Australia.

Lacosamide is used for the treatment of seizures improving the life of patients suffering from epilepsy. The tablets will be marketed in Australia in the strengths 50mg, 100mg, 150mg, and 200mg by our partner, one of the biggest generic pharmaceutical companies in the world. Our product has already been launched in time in several patent-free European markets. A launch in further countries will follow as soon as the patents of the originator product expire. With this early market entry, TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com

 


TIEFENBACHER GROUP STANDS WITH UKRAINE

To us at TIEFENBACHER GROUP, it is unbearable to witness what is happening in Ukraine. We condemn the Russian state´s invasion as a brutal act of war against a neighbouring sovereign country. Our thoughts are with everyone affected by this war. We stand with all Ukrainians and have already donated urgently needed medicine to a hospital in Kyiv and are currently checking further supply options. To support emergency aid for children and families in Ukraine we have also made a significant monetary donation to UNICEF.

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.

For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com.


MEET TIEFENBACHER GROUP DURING DCAT WEEK IN NEW YORK CITY FROM 21-24th MARCH!

Reach out to TIEFENBACHER GROUP at DCAT in New York City from 21-24th March and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before! Contact us to schedule a meeting via info@aet.eu.

For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients ́ lives by creating pharmaceuticals more affordable, more available, and better than before.


Featured Video Play Icon

TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!

We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three main locations in Hamburg (Germany), Hyderabad (India) and Lefkosia (Cyprus).

For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a value-driven and patient-focused healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients ́ lives by creating pharmaceuticals more affordable, more available, and better than before.


Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities

Did you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world?

As fully integrated pharmaceutical company, we offer a competitive supply chain management through our two own manufacturing plants in India and Cyprus. Our facilities are equipped with sophisticated technology from the first manufacturing step throughout to the last packaging step and warehousing. We are flexible to manage small batch as well as high volume productions. While our SPC waiver site in Cyprus is your perfect plant for high volume production made in Europe, our FDA approved site in India is your ideal fit for special technologies and small batch production. Both sites are currently further enlarging their production capacities, equipment, and warehouse storage – to drive efficiency and meet the growing demand of our customers.

Our two own manufacturing sites as well as our global network of contract manufacturers allow us to manufacture nearly any kind of formulation and dosage form. No matter if a controlled drug or a special dosage form – our about 60 years experience and our excellent know how in terms of regulatory and quality requirements guarantee the best possible supply chain for you.

All our plants are equipped with highly qualified professionals and highest safety standards. This ensures full compliance with Good Manufacturing Practice (GMP). Apart from the most important governmental approvals, our sites are periodically inspected by leading pharmaceutical companies.

For further information about our manufacturing facilities and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.